Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes (2010)

Mitomo, K., Griesenbach, U., Inoue, M., Somerton, L., Meng, C., Akiba, E., Tabata, T., Ueda, Y., Frankel, G. M., Farley, R., Singh, C., Chan, M., Munkonge, F., Brum, A., Xenariou, S., Escudero-Garcia, S., Hasegawa, M. & Alton, E. W.

Mol Ther, 18, 1173-1182

Pubmed     Back to Papers List

Gene therapy for cystic fibrosis (CF) is making encouraging progress into clinical trials. However, further improvements in transduction efficiency are desired. To develop a novel gene transfer vector that is improved and truly effective for CF gene therapy, a simian immunodeficiency virus (SIV) was pseudotyped with envelope proteins from Sendai virus (SeV), which is known to efficiently transduce unconditioned airway epithelial cells from the apical side. This novel vector was evaluated in mice in vivo and in vitro directed toward CF gene therapy. Here, we show that (i) we can produce relevant titers of an SIV vector pseudotyped with SeV envelope proteins for in vivo use, (ii) this vector can transduce the respiratory epithelium of the murine nose in vivo at levels that may be relevant for clinical benefit in CF, (iii) this can be achieved in a single formulation, and without the need for preconditioning, (iv) expression can last for 15 months, (v) readministration is feasible, (vi) the vector can transduce human air-liquid interface (ALI) cultures, and (vii) functional CF transmembrane conductance regulator (CFTR) chloride channels can be generated in vitro. Our data suggest that this lentiviral vector may provide a step change in airway transduction efficiency relevant to a clinical programme of gene therapy for CF.

Site map


Contact Details
Follow us on Facebook
Events & Fundraising
Site Feedback
Site Search
The CF Trust


Information for Patients on Our Clinical Trial
Latest Clinical Trial News
Contact Details
Patient Identification Centres
Frequently Asked Questions


Consortium Members' Internal Website
About Us
How the Consortium Works
Profiles of the Strategy Group
Community Review
Prof David Porteous OBE
Oxford University Gene Medicine
Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial


Our Research
Optimisation of pDNA
Aerosol Delivery
Viral Vectors Development
Assay Development
Core Facilities
Consortium Patents


Clinical Programme
Clinical Team
Tracking Study
The Run-in Study
Single Dose Clinical Trial
Multi Dose Clinical Trial


Cystic Fibrosis
What is CF?
History of CF
Discovery of the CFTR Gene
What Causes CF?
CFTR Protein Structure
Cystic Fibrosis Links


Gene Therapy
Introduction to CF Gene Therapy
Why use Gene Therapy for CF?
Other CF Gene Therapy Groups
Examples of Successful Gene Therapy
Gene Therapy Links


Publications in Journals
Conference Posters & Presentations
JustGeneTherapy Lecture, Sept 2012
Book Chapters
Open Access Publications
Latest Publications


Medical Futures Innovation Award 2011
Introductory Video
What is a Lentivirus
Production of Lentiviruses
Progress to Date
Photo Gallery